Drug
Fisogatinib
Fisogatinib: highest development phase Phase 1, developed by Blueprint Medicines. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Blueprint Medicines
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fisogatinib (BLU-554) NCT02508467 | Phase 1 | Hepatocellular Carcinoma (HCC) |
Latest
No recent events.
Follow Fisogatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.